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Abstract
The human GHRL gene encodes a 117-aminoacid peptide, preproghrelin that is pro-
teolytically processed to yield two peptides: ghrelin and obestatin. Ghrelin is secreted 
to the bloodstream in two major forms, acylated ghrelin (with an n-octanoylation in 
the third serine residue) and desacyl ghrelin (the form lacking n-octanoylation). Ghre-
lin acylation, promoted by ghrelin O-acyltransferase (GOAT), is essential for binding to 
the growth hormone (GH) secretagogue receptor (GHS-R) 1a and for the main endo-
crine functions of acylated ghrelin, including the stimulation of GH release, induction 
of food intake and stimulation of adipogenesis. Although devoid of binding to GHS-R 
1a, desacyl ghrelin also displays orexigenic and adipogenic actions, whereas the role 
of obestatin in the regulation of energy balance remains unclear. The discovery of the 
widespread distribution of ghrelin and its receptor in the cardiovascular system opened 
a new research field in the role of ghrelin in the control of blood pressure and myocar-
dial function. indeed, ghrelin inhibits the apoptosis of cardiomyocytes and endothelial 
cells, ameliorates left ventricular function and reduces fibrosis after myocardial injury in 
experimental models. in humans, ghrelin improves endothelial function by increasing 
nitric oxide (NO) bioavailability, normalizes the altered balance between endothelin-1 
and NO in patients with metabolic syndrome and exerts performance-enhancing ef-
fects on myocardial function of patients with chronic heart failure. This review focuses 
on advances in cardiometabolic effects of ghrelin gene-derived products in rodents 
and humans, and the possible role of ghrelin as a therapeutic molecule for treating 
cardiometabolic diseases.
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introduction
The adipose tissue acts as an active 
endocrine organ, secreting a large 
number of hormones, growth factors, 
enzymes, cytokines, complement fac-
tors and matrix proteins, collectively 
termed adipokines (1,2). The physi-
ological and pathophysiological rel-
evance of adipokines in the homeo-
stasis of the cardiovascular system 
resides in their effects on blood pres-
sure, fibrinolysis, angiogenesis, coagu-
lation, vascular remodelling, insulin 
sensitivity and immunity, among oth-
ers (1,3,4). In this respect, adipokines 
participate either directly or indirectly 
in the regulation of several processes 
that contribute to the development of 
inflammation, atherogenesis, hyper-
tension, and insulin resistance (2). 
Obesity was classified as a major 
modifiable risk factor for cardiovas-
cular diseases by the American Heart 
Association and, by the American 
College of Cardiology guidelines for 
secondary prevention of coronary ar-
tery disease (5,6). Upper body excess 
adiposity is associated with increased 
incidence of cardiometabolic diseases 
Adipobiology 3, 2011
Cardiometabolic effects of ghrelin and obestatin22 Review
(CMD) including atherosclerosis, hypertension, type 2 dia-
betes mellitus and the metabolic syndrome (7-9). Moreover, it 
has been recently described that percentage of body fat is per 
se positively associated with well-known circulating cardiovas-
cular markers (10). The molecular mechanisms underlying the 
onset of obesity-associated CMD have not been completely dis-
entangled. In this sense, ghrelin gene-derived products might 
constitute an important link between both pathologies. 
Ghrelin constitutes a peptide hormone that stimulates appe-
tite and induces a positive energy balance, leading to body weight 
gain (11,12). Additionally, ghrelin exerts several cardiovascular 
effects, including cardioprotective effects against ischemia, en-
hancement of vasodilation, cardiotropic effects, and regulation 
of blood pressure (13). The present review focuses on advances 
in cardiometabolic effects of ghrelin gene-derived products in 
rodents and humans.
1. discovery of the components of the ghrelin system
1.1. Growth hormone (GH) secretagogue receptor (GHS-R)
GHS-R was cloned from the pituitary and arcuate, ventrome-
dial and infundibular hypothalamus of swine and humans in 
1996 (14). GHS-R is a seven transmembrane G-protein coupled 
receptor that acts on the pituitary gland and hypothalamus to 
stimulate GH release (14). The human GHSR gene maps on 
chromosome 3, at 3q26.31, and two transcripts are produced 
from the alternative splicing of this gene: GHS-R 1a and 1b. The 
transcript GHS-R 1a excises an intron, encodes a protein with 
366 aminoacids with seven transmembrane domains and it is 
considered the functional ghrelin receptor (14,15). The second 
transcript GHS-R 1b retains the intron, encodes a C-terminal-
ly truncated isoform of the ghrelin receptor, consisting of 289 
aminoacids and five transmembrane domains, and it does not 
stimulate GH release. Nevertheless, GHS-R 1b can attenuate the 
activity of GHS-R 1a by the formation of heterodimers (16).
1.2. G-protein-coupled receptor 39 (GPR39)
The G-protein-coupled receptor 39 (GPR39) was cloned to-
gether with another receptor, GPR38, from human foetal brain 
cDNA in 1997 (17). In 2005, Zhang and colleagues reported that 
GPR39 was the receptor for obestatin, a peptide encoded by 
the ghrelin gene (18). Nevertheless, other authors have failed to 
reproduce GPR39-binding ability to obestatin in vitro (18, 19). 
Current evidence is weighted heavily against a role for obestatin 
as a GPR39 agonist. The human GPR39 gene is located on chro-
mosome 2, at 21q21-q22, and generates two transcripts by alter-
native splicing: GPR39-1a and 1b (20). The transcript GPR39-
1a encodes a full-length receptor of 435 aminoacids, whereas 
the GPR39-1b encodes a protein that is identical in sequence 
to the full-length receptor between aminoacids 1–285, but after 
Leu285, the GPR39-1b transcript encodes Ser-Glu-Ser, followed 
by a stop codon; GPR39-1b is assumed to be non-functional 
(21). GPR39-1a is expressed selectively throughout the gastro-
intestinal tract, including the liver and pancreas as well as in 
the kidney and adipose tissue, whereas the truncated GPR39-1b 
form has a widespread expression, including the central nervous 
system, with the highest expression in the stomach and small 
intestine (20).
1.3. Ghrelin gene products (acylated ghrelin, desacyl ghrelin and 
obestatin) 
In 1999, the endogenous ligand for GHS-R, ghrelin, was isolated 
from rat stomach (11). Ghrelin is a 28-aminoacid peptide hor-
mone, synthesized by X/A-like cells in the mucosa of the gastric 
fundus (11, 22). Stomach and intestine constitute the two ma-
jor ghrelin-secreting tissues (11, 22, 23), but ghrelin is also syn-
thesized to a lesser extent in other tissues, including pancreas, 
kidney, gonads, heart or adipose tissue (24). The human GHRL 
gene maps on chromosome 3, at 3p26.25, comprises 4 exons and 
3 introns and encodes a 117-aminoacid polypeptide called pre-
proghrelin (Fig. 1) (25,26). This polypeptide contains a 23-ami-
noacid sequence signal at the N-terminal region, which is first 
cleaved by a putative signal peptidase resulting in proghrelin with 
94 aminoacids. The prohormone convertases 1 and 3 (PC1/3), 
PC2 and furin are the endoproteases responsible for the cleav-
age of proghrelin after Arg28, generating the N-terminal mature 
28-aminocid ghrelin peptide as well as the C-terminal fragment, 
called obestatin (25,27). After this cleavage, the lysine residue 
of obestatin is cleaved by carboxypeptidase E. Two major forms 
of ghrelin are present in plasma and stomach: acylated ghrelin 
(~5% of total ghrelin with the n-octanoyl modification at Ser3) 
and desacyl-ghrelin (~95% without the acylation) (28). Other 
shorter forms of ghrelin have been recently described, like des-
Gln14-ghrelin, but their role remains unknown (29).
1.4. Ghrelin O-acyltransferase (GOAT) 
Yang (30) and Gutiérrez (31) independently reported the en-
zyme that catalyzes the octanoylation of ghrelin in the endoplas-
mic reticulum, the ghrelin O-acyltransferase (GOAT), in 2008. 
GOAT is a porcupine-like enzyme that belongs to the family 
of membrane-bound O-acyltransferases (MBOAT), previously 
known as MBOAT4 (32). The expression sites of GOAT include 
stomach, intestine, colon and testis in rodents, and mainly in 
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are characterized by a preprandial rise and a postprandial fall, 
supporting its role in meal initiation (39). Moreover, total se-
rum ghrelin concentrations increase steadily during long-term 
fasting in rodents and humans (40), and are reduced after re-
feeding (40). In addition, administration of exogenous ghrelin 
stimulates appetite and increases food intake by the stimulation 
of hypothalamic neuropeptide Y/agouti-related peptide neurons 
expressing GHS-R 1a (41). The molecular mechanisms under-
lying the orexigenic effects of ghrelin involve the activation of 
hypothalamic AMP-activated protein kinase and inactivation of 
the de novo fatty acid synthetic pathway, resulting in decreased 
malonyl-CoA levels and leading to the activation of carnitine 
palmitoyltransferase 1 (42). Despite its orexigenic effect, obesity, 
insulin resistance, type 2 diabetes or the metabolic syndrome are 
associated with a paradoxical decrease in circulating total ghre-
lin levels (11,43,44). Nevertheless, these pathologies are associ-
ated with a dramatic reduction of plasma desacyl ghrelin con-
centrations, the most abundant circulating isoform of the hor-
stomach, intestine and pancreas in humans (33). The human 
MBOAT4 gene is located on chromosome 8, at 8p12, and en-
codes a protein of 435 aminoacids in which the residues Asp307 
and His338 are essential for its enzymatic activity (30, 31). It has 
been demonstrated in vitro that GOAT activity can be potently 
inhibited by an octanoylated ghrelin pentapeptide and other 
end-products, suggesting a negative feedback regulation on the 
production of acylated ghrelin (34). On the other hand, GOAT 
is regulated by nutrient availability, depends on specific dietary 
lipids as acylation substrates and links ingested lipids to energy 
expenditure and body fat mass (35).
2. control of body weight and adiposity induced by 
ghrelin gene-derived peptides
2.1. Orexigenic effects of ghrelin 
Ghrelin plays a major role in the short- and long-term regula-
tion of appetite and body weight, in addition to its ability to 
stimulate GH release (12,36-38). Circulating ghrelin levels 
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Figure 1. Synthesis and processing of ghrelin gene-derived peptides. Ghrelin is synthesized in the X/A-like cells of the mu-
cosa of the gastric fundus. The human GHRL gene is located on chromosome 3 and comprises 4 exons and 3 introns. The GHRL 
gene encodes a polypeptide of 117 aminoacids, called preproghrelin. This precursor has a signal peptide that is cleaved by the 
action of peptidases resulting in the proghrelin molecule. This peptide is processed by PC 1 and 3 (PC1/3), PC2, furin and car-
boxypeptidase e, resulting in two peptides, obestatin and desacyl ghrelin. GOAT is the enzyme responsible of the esterification 
of an octanoic acid at Ser3 residue in ghrelin peptide.
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mone, while plasma levels of acylated ghrelin remain unchanged 
or increased (45,46).
It was initially proposed that, contrary to the orexigenic ef-
fects of ghrelin, obestatin suppressed food intake and decreased 
body weight gain in rats, acting through the ghrelin receptor 
family member GPR39 (18). Obestatin levels are increased in 
fasted rats and, after re-feeding, plasma obestatin levels are sig-
nificantly decreased but recovered quickly (40). Nevertheless, 
current knowledge of the secretory profile of obestatin is inad-
equate to make a correlation with specific feeding-related behav-
iours (47). In addition, obestatin degrades rapidly in serum and, 
unlike ghrelin, is not able to cross the blood-brain-barrier by a 
saturable transport system to allow the peptide to interact with 
its putative receptor GPR39 in the brain (48). Moreover, Noguei-
ras and colleagues failed to observe any effect of obestatin on 
food intake, body weight, body composition, energy expendi-
ture, locomotor activity, respiratory quotient, or hypothalamic 
neuropeptides involved in energy balance regulation in rats 
(19). Therefore, the role of obestatin in the regulation of food 
intake remains unclear, and further investigations are required.
2.2. Adipogenic effects of ghrelin and obestatin
The adipose tissue also constitutes an important target for the 
adipogenic actions of ghrelin in rodents and humans (45). Ghre-
lin, GOAT and the receptors of ghrelin-related peptides, GHS-R 
1a and GPR39, are expressed in human adipose tissue, suggest-
ing an autocrine/paracrine effect of ghrelin in this tissue (45, 
49-51). GHRL gene expression increases during adipogenesis 
and preproghrelin knockdown reduces insulin-mediated adipo-
genesis in 3T3-L1 adipocytes (52). Acylated ghrelin modulates 
preadipocyte proliferation and promotes their differentiation 
to mature adipocytes by increasing the expression of master 
adipogenic factors, peroxisome proliferator-activated recep-
tor γ (PPARγ) and sterol regulatory element-binding protein 
(SREBP) (45, 53). In this sense, acylated and desacyl ghrelin 
directly stimulate the expression of several fat storage-related 
proteins, including acetyl-CoA carboxylase, fatty acid synthase, 
and lipoprotein lipase through both central mechanisms (54) 
and directly acting on human visceral adipocytes (45), thereby 
stimulating intracytoplasmic lipid accumulation. In addition, 
acylated ghrelin, desacyl ghrelin and obestatin attenuate iso-
proterenol-induced lipolysis through phosphatidyl-inositol-3 
kinase (PI3K)-dependent mechanisms in murine 3T3-L1 cells 
as well as in isolated rat visceral adipocytes (55, 56). It has been 
recently discovered an antagonist of GOAT that reduces body 
weight in wild-type mice but not in ghrelin-deficient mice (57).
Recent in vitro studies suggest that obestatin also modulates 
adipocyte metabolism and adipogenesis. Obestatin expression is 
increased during adipocyte differentiation and obestatin treat-
ment in 3T3-L1 adipocytes, in combination with isobutyl-me-
thyl-xanthine and dexamethasone, regulates the expression of 
the transcription factors PPARγ and CCAAT-enhancer-binding 
proteins α, β, λ (C/EBPα, C/EBPβ, C/EBPγ), and hence pro-
motes adipogenesis (58). Obestatin also decreases lipolysis in 
3T3-L1 cells (56).
3. Role of ghrelin gene-derived peptides in the control 
of the cardiovascular system
Ghrelin acts on the pituitary and hypothalamus to stimulate GH 
release, while GH and its mediator, insulin-like growth factor 
(IGF)-1, are anabolic hormones that are essential for myocardial 
development and performance. Nevertheless, ghrelin has car-
diovascular effects through GH-dependent and -independent 
mechanisms, as explained below. The analysis of ghrelin bind-
ing sites in the cardiovascular system by Katugampola and col-
leagues (59) showed a higher density of receptors in the myocar-
dium of the right atrium than in the left ventricle (LV), whereas 
aorta and pulmonary artery expressed more receptors than sa-
phenous vein or coronary artery. In this regard, the discovery 
of ghrelin receptors in the cardiovascular system opened a new 
research field on the role of ghrelin in the control of blood pres-
sure and myocardial function (60,61). 
3.1. Ghrelin acts as a cardioprotective hormone
The myocardium constitutes a source of ghrelin and obestatin 
(60), and GHS-R 1a is expressed in cardiomyocytes and other 
myocardial tissues (62), supporting the autocrine/paracrine ef-
fects of ghrelin in the heart. Acylated and desacyl ghrelin protect 
cardiomyocytes and endothelial cells against apoptosis through 
the activation of an intracellular survival pathway (63), whereas 
contradictory data have been reported regarding the effect of 
obestatin on cardiomyocyte viability (64, 65). Acylated ghrelin, 
des-Gln14-ghrelin and desacyl ghrelin show negative inotropic 
effects on papillary muscle by activating the release of cyclooxy-
genase metabolites in endocardial endothelium (66). Ghrelin 
improves the cachexia and the altered myocardial energy me-
tabolism in rats with heart failure (67,68). In humans, plasma 
ghrelin and obestatin levels are increased in cachexia associ-
ated with chronic heart failure (CHF) (69, 70). The beneficial 
hemodynamic effects of ghrelin on patients with CHF seem to 
be attributable to both a positive inotropism of GH and a fall in 
cardiac overload. Furthermore, intravenous administration of 
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ghrelin in healthy individuals and patients with CHF improves 
the cardiac function by increasing the cardiac index and stroke 
volume index (71,72). Nevertheless, hearts of patients with CHF 
exhibit an impaired ghrelin production which might reflect 
maladaptive processes and a probably compensatory increase in 
GHS-R 1a expression (62). 
Ghrelin exerts performance-enhancing effects on myocardial 
function. Chronic administration of ghrelin after myocardial in-
farction has been shown to attenuate LV enlargement and myo-
cardial fibrosis by the suppression of cardiac sympathetic activ-
ity in rodents (67,73). The analysis by tissue Doppler imaging 
in healthy, young, normal-weight men with chronic intravenous 
administration of ghrelin showed an increase in the tissue track-
ing, which reflects an improvement in the global longitudinal 
systolic contraction of LV amplitude (74). Common variants 
in the human GHSR gene, which are associated with parame-
ters of LV mass and geometry independently of blood pressure 
and BMI, have been identified in the general population (57). 
Moreover, a single-nucleotide polymorphism in the GHRL gene 
5’ flanking area (-501A>C) associated with LV mass index after 
adjustments for age, sex and systolic blood pressure has been 
recently described (75). In this sense, circulating acylated ghre-
lin concentrations are increased in patients with LV hypertrophy 
compared with those with appropriate LV mass, which might 
reflect the LV remodelling during the progression to LV hyper-
trophy (46).
3.2. Hypotensive effect of ghrelin
Growing evidence supports that ghrelin reduces arterial pres-
sure and systemic vascular resistance. Plasma ghrelin and 
obestatin levels are increased in hypertensive rats (76). Intracer-
ebroventricular administration of ghrelin into the nucleus of the 
solitary tract (brain region involved in the regulation of cardio-
vascular system) induces a decrease in blood pressure, heart rate 
and also suppressed sympathetic renal activity in experimental 
animals (77,78). Intravenous administration of obestatin does 
not change blood pressure values of spontaneously hyperten-
sive rats (SHR) (79). In humans, intravenous administration of 
ghrelin in healthy individuals and patients with CHF decreases 
mean arterial pressure, without changes in heart rate (69,70). In 
patients with the metabolic syndrome, high plasma concentra-
tions of acylated ghrelin are associated with significantly higher 
blood pressure values, even after adjusting for BMI (46). Given 
the physiological relevance of acylated ghrelin, its increased pro-
duction may represent a compensatory hypotensive mechanism.
Ghrelin causes vasorelaxation through different molecular 
mechanisms. Firstly, ghrelin improves endothelial dysfunc-
tion in GH-deficient rats by increasing endothelial nitric oxide 
(NO) synthase (eNOS) expression in the aorta, suggesting that 
this vascular effect is mediated by a GH-independent mecha-
nism (80). Ghrelin directly stimulates the production of NO 
from vascular endothelial cells using PI3K-dependent signal-
ling pathways that mimic those of insulin (81). In humans, in-
traarterial infusion of ghrelin induces vasodilation through GH/
IGF-1-independent mechanisms in healthy individuals (82) 
and reverses endothelial dysfunction in patients with metabolic 
syndrome by increasing NO bioactivity (83). Secondly, ghrelin 
inhibits vascular oxidative stress through the inhibition of vas-
cular NAD(P)H oxidases activity in SHR (84). In this regard, 
systemic administration of desacyl ghrelin, but not acylated 
ghrelin, prevented diabetes-induced endothelial progenitor cell 
damage by modulating the NADPH oxidase regulatory protein 
Rac1 and improved the vasculogenic potential in individuals 
with type 2 diabetes (85). Ghrelin also inhibits proinflammatory 
cytokine production, mononuclear cell binding, and nuclear 
factor-κB (NFκB) activation in human endothelial cells in vitro, 
and hence, reduces the endothelial inflammation (86). Finally, 
ghrelin exerts an endothelium-independent depressor action 
in rat aorta by inhibiting angiotensin II-induced vasoconstric-
tion (87). Furthermore, ghrelin constitutes an effective endothe-
lium-independent vasodilator of the long-lasting constrictor 
endothelin-1 in human internal mammary arteries producing 
responses similar to those of adrenomedullin (88). Infusion of 
ghrelin in patients with metabolic syndrome restores the bal-
ance between vasoconstrictor endothelin-1 and vasodilator NO 
mediators (89). In summary, ghrelin increases NO bioavailabil-
ity, prevents vascular oxidative stress and antagonizes the con-
traction of potent vasoconst rictor peptides, thereby preserving 
vascular homeostasis.
4. conclusions
In summary, ghrelin exerts important cardiovascular actions in 
addition to its orexigenic and adipogenic effects, as shown in 
Figure 2. On the contrary, the contradictory observations of the 
role of obestatin in the viability of cardiomyocytes raise some 
questions regarding its involvement as a cardioprotective hor-
mone (64,65). Further studies will be necessary to establish the 
specific contribution of obestatin in the myocardium. Likewise, 
further investigations in novel mutations, single-nucleotide 
polymorphisms or differential expression levels of molecules of 
the ghrelin system are needed to broaden our understanding of 
their role in the onset of obesity-associated CMD.
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